Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study

Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic d...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-02, Vol.9 (2), p.e88177-e88177
Main Authors: Assmann, Gunter, Shihadeh, Klara, Poeschel, Viola, Murawski, Niels, Conigliarou, Jutta, Ong, Mei Fang, Pfreundschuh, Michael
Format: Article
Language:English
Subjects:
Antibodies
Arthritis
Autoantibodies
Autoantibodies - blood
B-cell lymphoma
Blood & organ donations
Cardiovascular disease
Case-Control Studies
Chemotherapy
Citrulline
Drug dosages
Epidemiology
Family medical history
Female
Gene therapy
Humans
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Immunoglobulins
Internal medicine
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - blood
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - mortality
Male
Medical prognosis
Medical schools
Medicine
Middle Aged
Patients
Peptides
Peptides, Cyclic - immunology
Population
Prognosis
Proteins
Rheumatoid arthritis
Seroepidemiologic Studies
Statistical analysis
Statistical tests
Stem cells
Studies
Subgroups
Survival
Survival Rate
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93
cites cdi_FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93
container_end_page e88177
container_issue 2
container_start_page e88177
container_title PloS one
container_volume 9
creator Assmann, Gunter
Shihadeh, Klara
Poeschel, Viola
Murawski, Niels
Conigliarou, Jutta
Ong, Mei Fang
Pfreundschuh, Michael
description Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value
doi_str_mv 10.1371/journal.pone.0088177
format article
fullrecord <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1496070445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_67569d3822fc4adc953cd25bd7cd3666</doaj_id><sourcerecordid>1499135444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93</originalsourceid><addsrcrecordid>eNptUk2P0zAQjRCIXRb-AQJLXLqHFH_FSTggdcvXSpXYA5ytie20rtw42M6i_gL-NmmbXe0iTrZm3rx58_Sy7DXBc8JK8n7rh9CBm_e-M3OMq4qU5ZPsnNSM5oJi9vTB_yx7EeMW44JVQjzPzigviBC4PM_-3ARzC850yiDfIuiSzZVNYXDOdpCMRn3wydju2Gq8tiai2WJ5s7hEY7GHZE2XIvpt0wZp27ZDNMhBWBt0lSvjHHL7Xb_xO0CzT6ur5eryAwKkIJpc-S4F71BMg96_zJ614KJ5Nb0X2c8vn38sv-Wr71-vl4tVrgoqUs4IU62ijFIuagMNrhhtATRvFGG8rLQiuNZaaGbG27WiQtdkLEPdsqpRNbvI3p54e-ejnDyMkvB6tANzXoyI6xNCe9jKPtgdhL30YOWx4MNaQkhWOSNFWYhas4rSVnHQqi6Y0rRodKk0E0KMXB-nbUOzM1qNVgVwj0gfdzq7kWt_K9lBtShHgtlEEPyvwcQkdzYebIXO-OGouyas4JyP0Hf_QP9_HT-hVPAxBtPeiyFYHnJ1NyUPuZJTrsaxNw8PuR-6CxL7C7cazIQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1496070445</pqid></control><display><type>article</type><title>Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Assmann, Gunter ; Shihadeh, Klara ; Poeschel, Viola ; Murawski, Niels ; Conigliarou, Jutta ; Ong, Mei Fang ; Pfreundschuh, Michael</creator><contributor>Pietropaolo, Massimo</contributor><creatorcontrib>Assmann, Gunter ; Shihadeh, Klara ; Poeschel, Viola ; Murawski, Niels ; Conigliarou, Jutta ; Ong, Mei Fang ; Pfreundschuh, Michael ; Pietropaolo, Massimo</creatorcontrib><description>Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value &lt;0.05 was statistically significant. ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0088177</identifier><identifier>PMID: 24516607</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antibodies ; Arthritis ; Autoantibodies ; Autoantibodies - blood ; B-cell lymphoma ; Blood &amp; organ donations ; Cardiovascular disease ; Case-Control Studies ; Chemotherapy ; Citrulline ; Drug dosages ; Epidemiology ; Family medical history ; Female ; Gene therapy ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Immunoglobulins ; Internal medicine ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - blood ; Lymphoma, Large B-Cell, Diffuse - immunology ; Lymphoma, Large B-Cell, Diffuse - mortality ; Male ; Medical prognosis ; Medical schools ; Medicine ; Middle Aged ; Patients ; Peptides ; Peptides, Cyclic - immunology ; Population ; Prognosis ; Proteins ; Rheumatoid arthritis ; Seroepidemiologic Studies ; Statistical analysis ; Statistical tests ; Stem cells ; Studies ; Subgroups ; Survival ; Survival Rate ; Tumor necrosis factor-TNF</subject><ispartof>PloS one, 2014-02, Vol.9 (2), p.e88177-e88177</ispartof><rights>2014 Assmann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Assmann et al 2014 Assmann et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93</citedby><cites>FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1496070445/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1496070445?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24516607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Pietropaolo, Massimo</contributor><creatorcontrib>Assmann, Gunter</creatorcontrib><creatorcontrib>Shihadeh, Klara</creatorcontrib><creatorcontrib>Poeschel, Viola</creatorcontrib><creatorcontrib>Murawski, Niels</creatorcontrib><creatorcontrib>Conigliarou, Jutta</creatorcontrib><creatorcontrib>Ong, Mei Fang</creatorcontrib><creatorcontrib>Pfreundschuh, Michael</creatorcontrib><title>Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value &lt;0.05 was statistically significant. ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.</description><subject>Antibodies</subject><subject>Arthritis</subject><subject>Autoantibodies</subject><subject>Autoantibodies - blood</subject><subject>B-cell lymphoma</subject><subject>Blood &amp; organ donations</subject><subject>Cardiovascular disease</subject><subject>Case-Control Studies</subject><subject>Chemotherapy</subject><subject>Citrulline</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>Family medical history</subject><subject>Female</subject><subject>Gene therapy</subject><subject>Humans</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulins</subject><subject>Internal medicine</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - blood</subject><subject>Lymphoma, Large B-Cell, Diffuse - immunology</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical schools</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Peptides</subject><subject>Peptides, Cyclic - immunology</subject><subject>Population</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Rheumatoid arthritis</subject><subject>Seroepidemiologic Studies</subject><subject>Statistical analysis</subject><subject>Statistical tests</subject><subject>Stem cells</subject><subject>Studies</subject><subject>Subgroups</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumor necrosis factor-TNF</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk2P0zAQjRCIXRb-AQJLXLqHFH_FSTggdcvXSpXYA5ytie20rtw42M6i_gL-NmmbXe0iTrZm3rx58_Sy7DXBc8JK8n7rh9CBm_e-M3OMq4qU5ZPsnNSM5oJi9vTB_yx7EeMW44JVQjzPzigviBC4PM_-3ARzC850yiDfIuiSzZVNYXDOdpCMRn3wydju2Gq8tiai2WJ5s7hEY7GHZE2XIvpt0wZp27ZDNMhBWBt0lSvjHHL7Xb_xO0CzT6ur5eryAwKkIJpc-S4F71BMg96_zJ614KJ5Nb0X2c8vn38sv-Wr71-vl4tVrgoqUs4IU62ijFIuagMNrhhtATRvFGG8rLQiuNZaaGbG27WiQtdkLEPdsqpRNbvI3p54e-ejnDyMkvB6tANzXoyI6xNCe9jKPtgdhL30YOWx4MNaQkhWOSNFWYhas4rSVnHQqi6Y0rRodKk0E0KMXB-nbUOzM1qNVgVwj0gfdzq7kWt_K9lBtShHgtlEEPyvwcQkdzYebIXO-OGouyas4JyP0Hf_QP9_HT-hVPAxBtPeiyFYHnJ1NyUPuZJTrsaxNw8PuR-6CxL7C7cazIQ</recordid><startdate>20140207</startdate><enddate>20140207</enddate><creator>Assmann, Gunter</creator><creator>Shihadeh, Klara</creator><creator>Poeschel, Viola</creator><creator>Murawski, Niels</creator><creator>Conigliarou, Jutta</creator><creator>Ong, Mei Fang</creator><creator>Pfreundschuh, Michael</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140207</creationdate><title>Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study</title><author>Assmann, Gunter ; Shihadeh, Klara ; Poeschel, Viola ; Murawski, Niels ; Conigliarou, Jutta ; Ong, Mei Fang ; Pfreundschuh, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibodies</topic><topic>Arthritis</topic><topic>Autoantibodies</topic><topic>Autoantibodies - blood</topic><topic>B-cell lymphoma</topic><topic>Blood &amp; organ donations</topic><topic>Cardiovascular disease</topic><topic>Case-Control Studies</topic><topic>Chemotherapy</topic><topic>Citrulline</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>Family medical history</topic><topic>Female</topic><topic>Gene therapy</topic><topic>Humans</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulins</topic><topic>Internal medicine</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - blood</topic><topic>Lymphoma, Large B-Cell, Diffuse - immunology</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical schools</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Peptides</topic><topic>Peptides, Cyclic - immunology</topic><topic>Population</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Rheumatoid arthritis</topic><topic>Seroepidemiologic Studies</topic><topic>Statistical analysis</topic><topic>Statistical tests</topic><topic>Stem cells</topic><topic>Studies</topic><topic>Subgroups</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Assmann, Gunter</creatorcontrib><creatorcontrib>Shihadeh, Klara</creatorcontrib><creatorcontrib>Poeschel, Viola</creatorcontrib><creatorcontrib>Murawski, Niels</creatorcontrib><creatorcontrib>Conigliarou, Jutta</creatorcontrib><creatorcontrib>Ong, Mei Fang</creatorcontrib><creatorcontrib>Pfreundschuh, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Assmann, Gunter</au><au>Shihadeh, Klara</au><au>Poeschel, Viola</au><au>Murawski, Niels</au><au>Conigliarou, Jutta</au><au>Ong, Mei Fang</au><au>Pfreundschuh, Michael</au><au>Pietropaolo, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-02-07</date><risdate>2014</risdate><volume>9</volume><issue>2</issue><spage>e88177</spage><epage>e88177</epage><pages>e88177-e88177</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value &lt;0.05 was statistically significant. ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24516607</pmid><doi>10.1371/journal.pone.0088177</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2014-02, Vol.9 (2), p.e88177-e88177
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1496070445
source Publicly Available Content Database; PubMed Central
subjects Antibodies
Arthritis
Autoantibodies
Autoantibodies - blood
B-cell lymphoma
Blood & organ donations
Cardiovascular disease
Case-Control Studies
Chemotherapy
Citrulline
Drug dosages
Epidemiology
Family medical history
Female
Gene therapy
Humans
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Immunoglobulins
Internal medicine
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - blood
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - mortality
Male
Medical prognosis
Medical schools
Medicine
Middle Aged
Patients
Peptides
Peptides, Cyclic - immunology
Population
Prognosis
Proteins
Rheumatoid arthritis
Seroepidemiologic Studies
Statistical analysis
Statistical tests
Stem cells
Studies
Subgroups
Survival
Survival Rate
Tumor necrosis factor-TNF
title Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A26%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20anti-citrullinated%20protein%20antibodies%20(ACPA)%20in%20patients%20with%20diffuse%20large%20B-cell%20lymphoma%20(DLBCL):%20a%20case-control%20study&rft.jtitle=PloS%20one&rft.au=Assmann,%20Gunter&rft.date=2014-02-07&rft.volume=9&rft.issue=2&rft.spage=e88177&rft.epage=e88177&rft.pages=e88177-e88177&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0088177&rft_dat=%3Cproquest_plos_%3E1499135444%3C/proquest_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c526t-313cfc2322469eab0832faad4bc13478dc109dd6d3e932dc26d9178da9f38bc93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1496070445&rft_id=info:pmid/24516607&rfr_iscdi=true